Molecular Assessment for Gastro-Esophageal Cancer

NCT06346054 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2026-02-17

No results posted yet for this study

Summary

The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for gastro-oesophageal cancer.

The main questions this study aims to answer:

Are oncometabolites proficient and reproducible enough to function as diagnostic biomarkers? Can these biomarkers identify early-stage gastro-esophageal cancer? Researchers will compare participants with gastro-oesophageal cancer to healthy controls and participants with Barrett's esophagus to detect meaningful differences between the groups.

Participants will provide a breath and blood sample during their routine standard of care visits.

Conditions

Interventions

DIAGNOSTIC_TEST

Breath analysis

Detection of proteins and volatile organic compounds (oncometabolites) in the exhaled breath

DIAGNOSTIC_TEST

Blood analysis

Detection of proteins and circulating tumor DNA (oncometabolites) in the peripheral blood

Sponsors & Collaborators

  • KU Leuven

    lead OTHER

Principal Investigators

  • Stijn Vanstraelen, MD · Universitaire Ziekenhuizen KU Leuven

  • Philippe Nafteux, MD, PhD · Universitaire Ziekenhuizen KU Leuven

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2029-07-01
Completion
2029-07-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06346054 on ClinicalTrials.gov